• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肥胖与心力衰竭:探索心脏代谢轴。

Obesity and heart failure: exploring the cardiometabolic axis.

作者信息

Rayner Jennifer J, Abdesselam Ines, Pan Jiliu, Lewis Andrew J M, Rider Oliver J

机构信息

Oxford Centre for Clinical Magnetic Resonance Research, Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DU, UK.

出版信息

Cardiovasc Res. 2025 Jul 31;121(8):1173-1186. doi: 10.1093/cvr/cvaf090.

DOI:10.1093/cvr/cvaf090
PMID:40458047
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12310286/
Abstract

Obesity is one of the biggest risks to public health in both developed and developing countries, and yet incidence continues to skyrocket. Being the main risk factor for a large number of life-limiting conditions, obesity has the potential to cause enormous damage unless addressed urgently. Heart failure (HF) is the most common cardiovascular disease associated with obesity. The incidence of HF overall continues to rise and mortality rates remain high, despite the rapid and significant advances in pharmacotherapy that have recently transformed the landscape of HF treatment. Both obesity and heart failure are multisystem disorders that are closely interlinked. Obesity poses the body a number of challenges, ranging from haemodynamic, to neuroendocrine, to inflammatory, to intracellular physiology. This narrative review describes the pathophysiological 'vicious cycle' caused by the combination of obesity and HF. Management of obesity in established heart failure has for years been a controversial topic, and yet an increasing body of evidence suggests that there are numerous benefits to managing obesity and insulin resistance in heart failure. Here, we review the existing evidence base, as well as exciting new developments, suggesting that we may finally be on the brink of a revolution in managing obesity in heart failure.

摘要

肥胖是发达国家和发展中国家公共卫生面临的最大风险之一,然而其发病率仍在持续飙升。作为大量危及生命疾病的主要风险因素,肥胖若不紧急应对,有可能造成巨大损害。心力衰竭(HF)是与肥胖相关的最常见心血管疾病。尽管药物治疗最近取得了迅速而重大的进展,改变了HF治疗的格局,但HF的总体发病率仍在上升,死亡率依然居高不下。肥胖和心力衰竭都是密切相关的多系统疾病。肥胖给身体带来了诸多挑战,从血流动力学、神经内分泌、炎症到细胞内生理学等方面。这篇叙述性综述描述了由肥胖和HF共同作用导致的病理生理“恶性循环”。多年来,在已确诊心力衰竭的情况下对肥胖进行管理一直是一个有争议的话题,但越来越多的证据表明,在心力衰竭中管理肥胖和胰岛素抵抗有诸多益处。在此,我们回顾现有的证据基础以及令人振奋的新进展,这表明我们或许终于正处在心力衰竭肥胖管理变革的边缘。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e6ba/12310286/a7b11c7b4188/cvaf090f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e6ba/12310286/39520d425508/cvaf090f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e6ba/12310286/6ce1ae05c978/cvaf090f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e6ba/12310286/f217dacbab2c/cvaf090f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e6ba/12310286/2bd4a7638dd7/cvaf090f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e6ba/12310286/a7b11c7b4188/cvaf090f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e6ba/12310286/39520d425508/cvaf090f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e6ba/12310286/6ce1ae05c978/cvaf090f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e6ba/12310286/f217dacbab2c/cvaf090f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e6ba/12310286/2bd4a7638dd7/cvaf090f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e6ba/12310286/a7b11c7b4188/cvaf090f5.jpg

相似文献

1
Obesity and heart failure: exploring the cardiometabolic axis.肥胖与心力衰竭:探索心脏代谢轴。
Cardiovasc Res. 2025 Jul 31;121(8):1173-1186. doi: 10.1093/cvr/cvaf090.
2
The Black Book of Psychotropic Dosing and Monitoring.《精神药物剂量与监测黑皮书》
Psychopharmacol Bull. 2024 Jul 8;54(3):8-59.
3
Systemic treatments for metastatic cutaneous melanoma.转移性皮肤黑色素瘤的全身治疗
Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2.
4
Management of urinary stones by experts in stone disease (ESD 2025).结石病专家对尿路结石的管理(2025年结石病专家共识)
Arch Ital Urol Androl. 2025 Jun 30;97(2):14085. doi: 10.4081/aiua.2025.14085.
5
Factors that influence participation in physical activity for people with bipolar disorder: a synthesis of qualitative evidence.影响双相障碍患者参与体育活动的因素:定性证据的综合分析。
Cochrane Database Syst Rev. 2024 Jun 4;6(6):CD013557. doi: 10.1002/14651858.CD013557.pub2.
6
Mechanistic Relevance of Ventricular Arrhythmias in Heart Failure with Preserved Ejection Fraction.射血分数保留的心力衰竭中心律失常的机制相关性
Int J Mol Sci. 2024 Dec 14;25(24):13423. doi: 10.3390/ijms252413423.
7
Interventions for weight reduction in obesity to improve survival in women with endometrial cancer.肥胖症减肥干预措施以提高子宫内膜癌女性的生存率。
Cochrane Database Syst Rev. 2023 Mar 27;3(3):CD012513. doi: 10.1002/14651858.CD012513.pub3.
8
Weight loss interventions for chronic asthma.慢性哮喘的体重减轻干预措施。
Cochrane Database Syst Rev. 2012 Jul 11;2012(7):CD009339. doi: 10.1002/14651858.CD009339.pub2.
9
Systemic Inflammatory Response Syndrome全身炎症反应综合征
10
Antidepressants for pain management in adults with chronic pain: a network meta-analysis.抗抑郁药治疗成人慢性疼痛的疼痛管理:一项网络荟萃分析。
Health Technol Assess. 2024 Oct;28(62):1-155. doi: 10.3310/MKRT2948.

本文引用的文献

1
Definition and diagnostic criteria of clinical obesity.临床肥胖的定义和诊断标准。
Lancet Diabetes Endocrinol. 2025 Mar;13(3):221-262. doi: 10.1016/S2213-8587(24)00316-4. Epub 2025 Jan 14.
2
Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity.替尔泊肽用于射血分数保留的心力衰竭合并肥胖症
N Engl J Med. 2025 Jan 30;392(5):427-437. doi: 10.1056/NEJMoa2410027. Epub 2024 Nov 16.
3
Cardiovascular outcomes with exenatide in type 2 diabetes according to ejection fraction: The EXSCEL trial.根据射血分数评估艾塞那肽用于2型糖尿病患者的心血管结局:EXSCEL试验
Eur J Heart Fail. 2025 Mar;27(3):540-551. doi: 10.1002/ejhf.3478. Epub 2024 Oct 9.
4
Effect of Semaglutide on Cardiac Structure and Function in Patients With Obesity-Related Heart Failure.司美格鲁肽对肥胖相关性心力衰竭患者心脏结构和功能的影响。
J Am Coll Cardiol. 2024 Oct 22;84(17):1587-1602. doi: 10.1016/j.jacc.2024.08.021. Epub 2024 Aug 30.
5
Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial.司美格鲁肽在肥胖合并心力衰竭患者中的心血管结局:SELECT 试验的预先指定分析。
Lancet. 2024 Aug 24;404(10454):773-786. doi: 10.1016/S0140-6736(24)01498-3.
6
Anthropometric measures and long-term mortality in non-ischaemic heart failure with reduced ejection fraction: Questioning the obesity paradox.射血分数降低的非缺血性心力衰竭患者的人体测量指标与长期死亡率:质疑肥胖悖论
Eur J Heart Fail. 2025 Mar;27(3):527-536. doi: 10.1002/ejhf.3424. Epub 2024 Aug 18.
7
Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies.基于胰高血糖素样肽-1 的治疗方法和缓解策略对去脂体重的影响。
Diabetes Obes Metab. 2024 Sep;26 Suppl 4:16-27. doi: 10.1111/dom.15728. Epub 2024 Jun 27.
8
Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes.司美格鲁肽治疗肥胖相关性心力衰竭合并 2 型糖尿病患者的效果。
N Engl J Med. 2024 Apr 18;390(15):1394-1407. doi: 10.1056/NEJMoa2313917. Epub 2024 Apr 6.
9
A second chance for a new heart? The role of metabolic and bariatric surgery in patients with end-stage heart failure.新的心脏是否有第二次机会?代谢和减重手术在终末期心力衰竭患者中的作用。
J Gastrointest Surg. 2024 Apr;28(4):389-393. doi: 10.1016/j.gassur.2024.02.013. Epub 2024 Feb 9.
10
Body mass index and cardiorenal outcomes in the EMPEROR-Preserved trial: Principal findings and meta-analysis with the DELIVER trial.EMPEROR-Preserved试验中的体重指数与心肾结局:主要发现及与DELIVER试验的荟萃分析
Eur J Heart Fail. 2024 Apr;26(4):900-909. doi: 10.1002/ejhf.3221. Epub 2024 Apr 1.